Abvc Biopharma (ABVC) Short-Term Debt repayments (2015 - 2020)
Abvc Biopharma's (ABVC) quarterly Short-Term Debt repayments came in at -$23757.0 in Q4 2020, down 346.72% on a YoY basis from $9629.0 in Q1 2020, and up 16.45% quarter-over-quarter from -$28434.0 in Q3 2020.
Powered by 
Analysis
Abvc Biopharma (ABVC) Short-Term Debt repayments (2015 - 2020) Analysis & Trends
Abvc Biopharma (ABVC) has reported Short-Term Debt repayments for 3 consecutive years, with -$23757.0 the latest figure, recorded in Q4 2020.
- For the quarter ending Q4 2020, Short-Term Debt repayments fell 346.72% year-over-year to -$23757.0; the trailing twelve-month figure through Dec 2020 stood at -$42517.0 (changed N/A YoY), and the FY2021 full-year result was -$23044.0, down 2323.13% from the prior year.
- Short-Term Debt repayments rose to -$23757.0 in Q4 2020 per ABVC's latest filing, from -$28434.0 in the prior quarter.
- Across five years, Short-Term Debt repayments topped out at $9629.0 in Q4 2019 and bottomed at -$28434.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | -23,757.00 |
| Sep 30, 2020 | -28,434.00 |
| Dec 31, 2019 | 9,629.00 |
| Sep 30, 2019 | 45.00 |
| Dec 31, 2015 | -7,000.00 |